Skip to main content

Table 1 Comparison of the half-life and PPARγ binding affinities of MSDC-0160 and commonly used TZDs

From: Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration

Drug PPARγ binding IC 50 (μM) MPC binding (μM) C max /half life
Rosiglitazone 0.112 1.1 1 µM/3–4 h
Pioglitazone 1.535 1.2 4 µM/5–8 h
MSDC-0160 31.648 1.2 12 µM/12 h